| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| 100mg | |||
| Other Sizes |
| Targets |
dmDNA31 targets bacterial DNA-dependent RNA polymerase, inhibiting its enzymatic activity. As a rifamycin-class antibiotic, it binds to the beta-subunit of bacterial RNA polymerase and blocks transcription elongation. The compound exhibits potent bactericidal activity specifically against Staphylococcus aureus. Its mechanism involves inhibition of bacterial RNA synthesis, leading to bacterial cell death. The compound's selectivity for bacterial RNA polymerase over the mammalian enzyme contributes to its antibacterial activity with reduced host toxicity.
|
|---|---|
| ln Vitro |
In vitro studies have characterized dmDNA31 as a potent inhibitor of bacterial DNA-dependent RNA polymerase with strong bactericidal activity against Staphylococcus aureus. The compound's activity has been demonstrated in biochemical assays measuring RNA polymerase inhibition and in bacterial culture assays measuring growth inhibition. As a rifamycin-class antibiotic, dmDNA31's mechanism and potency are consistent with other members of this class. The compound's specific activity against S. aureus has been confirmed in multiple assays. Its antibacterial spectrum and potency have been characterized in vitro.
|
| ln Vivo |
In vivo studies of dmDNA31 are limited in the available literature. As a rifamycin-class antibiotic with potent activity against Staphylococcus aureus, the compound would be expected to have efficacy in animal models of S. aureus infection. However, specific in vivo efficacy data are not extensively reported. The compound is a research tool for studying bacterial transcription and developing antibacterial agents. Further studies would be required to fully characterize its in vivo activity and therapeutic potential.
|
| Enzyme Assay |
The in vitro enzyme assay for dmDNA31 involves measuring bacterial DNA-dependent RNA polymerase activity in the presence of varying concentrations of the compound. Purified RNA polymerase from S. aureus or other bacteria is incubated with a DNA template, nucleotides, and the compound. RNA synthesis is measured using radiolabeled nucleotides or fluorescent detection methods. The inhibition of RNA polymerase activity is determined from dose-response curves. As a rifamycin-class antibiotic, dmDNA31's mechanism involves binding to the beta-subunit of RNA polymerase. Data analysis yields IC50 values.
|
| Cell Assay |
In vitro cellular assays for dmDNA31 are conducted using bacterial cultures, particularly Staphylococcus aureus. Bacteria are grown in liquid culture and treated with varying concentrations of dmDNA31. Bacterial growth is monitored by measuring optical density at 600 nm (OD600) or by plating for colony-forming units (CFU) to determine bactericidal activity. Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) are determined. The compound's specificity is confirmed by testing against other bacterial species and comparing to control antibiotics. Time-kill assays can be performed to characterize the kinetics of bactericidal activity.
|
| Animal Protocol |
In vivo animal studies for dmDNA31 are not extensively reported. As a rifamycin-class antibiotic with activity against Staphylococcus aureus, the compound would be evaluated in animal models of S. aureus infection if being developed as a therapeutic agent. Typical models include murine thigh infection, skin infection, or sepsis models. However, specific in vivo efficacy studies are not available in the public domain. The compound is a research tool and is not currently approved for therapeutic use.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for dmDNA31 are not extensively reported. The compound has a molecular weight of 927.05 g/mol and a molecular formula of C50H62N4O13. As a rifamycin-class antibiotic, its pharmacokinetic properties would be similar to other rifamycins. Storage recommendations: powder should be stored at -20degC for up to 3 years or at 4degC; in solvent, it can be stored at -80degC for 6 months or at -20degC for 1 month. Specific PK parameters are not readily available. The compound is for research use only.
|
| Toxicity/Toxicokinetics |
Toxicology data for dmDNA31 are not extensively reported. As a rifamycin-class antibiotic, the compound's safety profile would be similar to other rifamycins, which can have side effects including gastrointestinal disturbances and hepatotoxicity. However, specific toxicity data, including LD50 values and organ toxicity profiles, are not available. The compound is for research use only and is not approved for therapeutic applications. Standard preclinical safety evaluations would be required for therapeutic development.
|
| References | |
| Additional Infomation |
dmDNA31 is a novel and potent antibiotic agent belonging to the rifamycin class that inhibits bacterial DNA-dependent RNA polymerase. It displays potent bactericidal activity specifically against Staphylococcus aureus. The compound has a molecular formula of C50H62N4O13 and a molecular weight of 927.05 g/mol. It is supplied as a purple to black solid powder with ≥95% purity. dmDNA31 is a research tool for studying bacterial transcription and developing antibacterial agents.
|
| Molecular Formula |
C50H62N4O13
|
|---|---|
| Molecular Weight |
927.046294689178
|
| Exact Mass |
926.431
|
| CAS # |
845625-44-7
|
| PubChem CID |
135428074
|
| Appearance |
Purple to black solid powder
|
| LogP |
3.3
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
67
|
| Complexity |
2490
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
C[C@H]1/C=C/C=C(\C(=O)NC2=C3C(=C4C(=C(C(=C5C4=C([C@](O5)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)C)O)C2=O)N=C6C(=CC(=CC6=O)N7CCC(CC7)N(C)C)O3)/C
|
| InChi Key |
GBSDCXVMKJSZDN-AWHPPKCISA-N
|
| InChi Code |
InChI=1S/C50H62N4O13/c1-23-13-12-14-24(2)49(62)52-40-44(60)36-35(39-47(40)66-34-22-31(21-32(56)38(34)51-39)54-18-15-30(16-19-54)53(9)10)37-46(28(6)43(36)59)67-50(8,48(37)61)64-20-17-33(63-11)25(3)45(65-29(7)55)27(5)42(58)26(4)41(23)57/h12-14,17,20-23,25-27,30,33,41-42,45,57-59,61H,15-16,18-19H2,1-11H3,(H,52,62)/b13-12+,20-17+,24-14-/t23-,25+,26+,27+,33-,41-,42+,45+,50-/m0/s1
|
| Chemical Name |
[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-30-[4-(dimethylamino)piperidin-1-yl]-2,6,15,17-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-23,32,37-trioxo-8,27,38-trioxa-24,34-diazahexacyclo[23.11.1.14,7.05,36.026,35.028,33]octatriaconta-1,3,5,9,19,21,25,28,30,33,35-undecaen-13-yl] acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~26.97 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.70 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.70 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0787 mL | 5.3935 mL | 10.7869 mL | |
| 5 mM | 0.2157 mL | 1.0787 mL | 2.1574 mL | |
| 10 mM | 0.1079 mL | 0.5393 mL | 1.0787 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
